<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315341</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-CTN-0027</org_study_id>
    <secondary_id>U10DA013045</secondary_id>
    <nct_id>NCT00315341</nct_id>
  </id_info>
  <brief_title>Starting Treatment With Agonist Replacement Therapies (START)</brief_title>
  <official_title>Starting Treatment With Agonist Replacement Therapies (START)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Food and Drug Administration (FDA) has requested a study comparing buprenorphine/naloxone
      (BUP/NX) and methadone (MET) on indices of hepatic safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, multi-center, Phase 4 study to assess the changes in liver
      enzymes related to treatment with buprenorphine/naloxone (BUP/NX) and methadone (MET) in
      participants entering opioid agonist treatment. Randomization will be stratified, within
      site, according to normal versus abnormal screening liver function tests. Participants
      meeting entry criteria will be dosed for 24 weeks during the active phase of the study with
      assessment of liver function at weeks 1, 2, 4, 8, 12, 16, 20, 24 and with follow-up
      assessments at week 32. Clinicians will be encouraged to treat with adequate doses of BUP/NX
      and MET.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic Safety</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Participants were categorized according liver transaminase (ALT, AST) levels in blood comparing the baseline sample to any and all subsequent samples in the following manner:
A: both ALT and AST started at less than or equal to two times the ULN and remained at two times or less ULN throughout the study
B: either ALT or AST started at less than or equal to 2 x ULN and at any point in study exceeded 2 x ULN
C: Either ALT or AST started &gt; 2 x ULN, decreased (both ALT and AST) to &lt; 2 x ULN, and remained &lt; 2 x ULN
D: Either ALT or AST started &gt; 2 x ULN and remained above 2 x ULN throughout the study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1269</enrollment>
  <condition>Opiate-related Disorders</condition>
  <arm_group>
    <arm_group_label>Buprenorphine/Nx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the BUP/NX group, all participants will receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg buprenorphine increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methadone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For the MET group, all participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
    <description>Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.</description>
    <arm_group_label>Buprenorphine/Nx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.</description>
    <arm_group_label>Methadone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Were age 18 years or older,

          2. Met DSM-IV-TR criteria for opioid dependence,

          3. Were in good general health, or, in case of a medical/psychiatric condition requiring
             ongoing treatment, were under the care of a physician willing to continue
             participant's medical management and cooperate with study physicians,

          4. For female participants, use of one of the following acceptable methods of birth
             control:

               1. oral contraceptives

               2. barrier (diaphragm or condom) with spermicide

               3. IUD

               4. intrauterine progesterone contraceptive system

               5. levonorgestrel implant

               6. medroxyprogesterone acetate contraceptive injection

               7. contraceptive transdermal patch

               8. hormonal vaginal contraceptive ring

               9. surgical sterilization

              10. complete abstinence from sexual intercourse

          5. Able to read and verbalize understanding of the study and voluntarily sign study
             informed consent form.

        Exclusion Criteria:

          1. ALT or AST values &gt; 5 times the upper limit of normal as per testing laboratory range
             criteria,

          2. ALP values &gt;3 times the upper limit of normal per testing laboratory criteria,

          3. Any documented past or present history of ascites, presence of esophageal or gastric
             varices, hepatic encephalopathy or other signs of significant liver disease as
             indicated by a Model for Endstage Liver Disease score (Kamath et al., 2001) of â‰¥11,

          4. Total bilirubin &gt; 2.0 mg/dl (participants with documented Gilbert's syndrome were not
             excluded based on this criterion),

          5. Prothrombin time more than 3 seconds prolonged,

          6. Albumin level less than 2.5 g/dl,

          7. Any cardiopathy or risk factor listed below without evidence of a normal ECG* with
             report performed within 6 months prior to first study medication dose,

               1. Congestive heart failure

               2. Left ventricular hypertrophy

               3. Bradycardia

               4. Hereditary QT prolongation

               5. Uncorrected electrolyte imbalance

               6. Concomitant medications that are known to have a risk of QT interval
                  prolongation; refer to Appendix D for a list of medications.

             Note: The list was not all-inclusive.

             *An ECG was abnormal if one or more of the following occurred:

             Significant ST segment abnormalities:

               -  ST segment elevations in two or more continuous leads of &gt; 0.1 mV

               -  ST segment depression of greater than 1 mm that are flat or down-sloping at 80
                  msec after the J point ST segment abnormalities identified as &quot;non-specific&quot; are
                  acceptable. If a potential participant's ECG indicated ST segment elevations or
                  depression consistent with ischemia, the physician obtained a medical history of
                  cardiac symptoms and referred the participant for evaluation.

             Conduction abnormalities:

               -  Mobitz II 2nd degree or 3rd degree heart block

               -  Atrial fibrillation, atrial flutter, or any non-sinus tachyarrhythmia

               -  Three or more consecutive ectopic ventricular complexes at a rate of &gt; 100 per
                  minute.

               -  QTc greater than 450 msec in men and 480 msec in women

             Repolarization abnormalities:

             â€¢ Acute medical condition that would make participation, in the opinion of the study
             physician, medically hazardous (e.g., unstable pancreatic, cardiovascular or renal
             disease, significant anemia)

          8. Known allergy or sensitivity to BUP, naloxone or MET or to any of the inactive
             ingredients in the study medications (including lactose, mannitol, cornstarch,
             povidone K30, citric acid, sodium citrate, FD&amp;C Yellow No.6 color, magnesium stearate,
             Acesulfame K sweetener)

          9. Known diagnosis of acute psychosis, severe depression or imminent suicide risk as
             determined via clinical interview by study physician or surrogates

         10. DSM-IV diagnosis of dependence on alcohol requiring immediate medical attention.

         11. DSM-IV diagnosis of dependence on benzodiazepines requiring immediate medical
             attention

         12. DSM-IV diagnosis of dependence on other depressants, or stimulants requiring immediate
             medical attention

         13. Participation in an investigational drug study within the past 30 days

         14. Treatment with MET, BUP/NX, or BUP for more than 15 of the past 30 days (illicit use
             of these medications is allowed)

         15. Pending legal action that could prohibit study participation

         16. Unable or unwilling to comply with study requirements

         17. Unable or unwilling to remain in the local area for duration of treatment

         18. Poor venous access such that venipuncture could not be accomplished from a vein in an
             extremity during eligibility

         19. Pregnant or lactating (females only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Ling, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Saxon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Matrix Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bi-Valley Medical Clinic INC.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAART; Turk Street Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Dispensary</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CT Counseling Centers</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addiction Research &amp; Treatment Corp</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CODA-Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NET Steps</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Treatment Services</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, Tasissa G, Lokhnygina Y, Leimberger J, Bruce RD, McCarthy J, Wiest K, McLaughlin P, Bilangi R, Cohen A, Woody G, Jacobs P. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013 Feb 1;128(1-2):71-6. doi: 10.1016/j.drugalcdep.2012.08.002. Epub 2012 Aug 22.</citation>
    <PMID>22921476</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2006</study_first_submitted>
  <study_first_submitted_qc>April 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2006</study_first_posted>
  <results_first_submitted>May 17, 2013</results_first_submitted>
  <results_first_submitted_qc>November 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2017</results_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Walter Ling</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Methadone clinics in California, Oregon, Washington, Pennsylvania, New York, and Connecticut</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine/Nx</title>
          <description>Participants received medication for 24 weeks in the active phase of the study. The mean dose of buprenorphine was 22.3 mg. Blood samples for measurement of liver function were taken at baseline and at Weeks 1, 2, 4 8, 12, 16, 20, and 24 with follow-up at Week 32.</description>
        </group>
        <group group_id="P2">
          <title>Methadone</title>
          <description>The mean dose of methadone was 93.2 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="740"/>
                <participants group_id="P2" count="529"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="340"/>
                <participants group_id="P2" count="391"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine/Nx</title>
        </group>
        <group group_id="B2">
          <title>Methadone</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="740"/>
            <count group_id="B2" value="529"/>
            <count group_id="B3" value="1269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.5" spread="11.2"/>
                    <measurement group_id="B2" value="37.3" spread="10.9"/>
                    <measurement group_id="B3" value="37.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="408"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="502"/>
                    <measurement group_id="B2" value="359"/>
                    <measurement group_id="B3" value="861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Safety</title>
        <description>Participants were categorized according liver transaminase (ALT, AST) levels in blood comparing the baseline sample to any and all subsequent samples in the following manner:
A: both ALT and AST started at less than or equal to two times the ULN and remained at two times or less ULN throughout the study
B: either ALT or AST started at less than or equal to 2 x ULN and at any point in study exceeded 2 x ULN
C: Either ALT or AST started &gt; 2 x ULN, decreased (both ALT and AST) to &lt; 2 x ULN, and remained &lt; 2 x ULN
D: Either ALT or AST started &gt; 2 x ULN and remained above 2 x ULN throughout the study</description>
        <time_frame>24 Weeks</time_frame>
        <population>evaluable subjects stayed in treatment for 24 weeks and gave at least 4 blood samples for liver function tests during the treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine/Nx</title>
          </group>
          <group group_id="O2">
            <title>Methadone</title>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Safety</title>
          <description>Participants were categorized according liver transaminase (ALT, AST) levels in blood comparing the baseline sample to any and all subsequent samples in the following manner:
A: both ALT and AST started at less than or equal to two times the ULN and remained at two times or less ULN throughout the study
B: either ALT or AST started at less than or equal to 2 x ULN and at any point in study exceeded 2 x ULN
C: Either ALT or AST started &gt; 2 x ULN, decreased (both ALT and AST) to &lt; 2 x ULN, and remained &lt; 2 x ULN
D: Either ALT or AST started &gt; 2 x ULN and remained above 2 x ULN throughout the study</description>
          <population>evaluable subjects stayed in treatment for 24 weeks and gave at least 4 blood samples for liver function tests during the treatment period</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT - A (low, stays low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278"/>
                    <measurement group_id="O2" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT - B (low, goes high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT - C (high, goes low, stays low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT - D (high, stays high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST - A (low, stay low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST - B (low, goes high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST - C (high, goes low, stays low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST - D (high, stays high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>categorized changes in ALT/AST from BL:(1)BL transaminases(both ALT/AST)â‰¤2X upper limit of normal(ULN)&amp; remained at this level;(2)BL transaminases â‰¤2X ULN(either ALT/AST)but increased(either ALT/AST)above this level at any time;(3)BL transaminases &gt;2X ULN(either ALT/AST)&amp; decreased and remained at â‰¤2X ULN(both ALT/AST);(4)BL transaminases(both ALT/AST)&gt;2X ULN &amp;remained at this level(both ALT/AST);(5)BL transaminases &gt;2X ULN(either ALT/AST)&amp; increased 2X above this level ever(either ALT/AST).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.05</p_value>
            <method>shift table analyses</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (medical and/or psychiatric) assessment will initiate with participant randomization and will continue through 30 days post last dose of study medication administered. Study staff should contact each participant 30 days after study completion and/or discontinuation of study medication to follow-up on any adverse events continuing at study end and to determine whether the participant experienced any adverse events within the 30 days after discontinuing study medication.</time_frame>
      <desc>All AEs reported during the course of the study requiring medical attention will be reported to a study physician immediately. A study physician may then meet any participants for whom additional follow-up or AE assessment is indicated. The type of AE, severity of the AE and the relationship of the AE to the study treatments will be assessed by appropriately trained medical personnel and recorded on an AE CRF, according to the procedures described in Section 14.2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine/Nx</title>
          <description>For the BUP/NX group, all participants will receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg buprenorphine increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participantâ€™s clinical need. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.</description>
        </group>
        <group group_id="E2">
          <title>Methadone</title>
          <description>For the MET group, all participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participantâ€™s clinical need with no specific upper limit. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedWatch</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="727"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="727"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>life-threatening</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="727"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>hospitalization</sub_title>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="727"/>
                <counts group_id="E2" events="50" subjects_affected="45" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>disability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>congenital anomaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="727"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedWatch</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="530" subjects_at_risk="727"/>
                <counts group_id="E2" subjects_affected="442" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" events="60" subjects_affected="49" subjects_at_risk="727"/>
                <counts group_id="E2" events="72" subjects_affected="55" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="52" subjects_affected="49" subjects_at_risk="727"/>
                <counts group_id="E2" events="51" subjects_affected="47" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="727"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="311" subjects_affected="196" subjects_at_risk="727"/>
                <counts group_id="E2" events="291" subjects_affected="174" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>general disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="99" subjects_affected="79" subjects_at_risk="727"/>
                <counts group_id="E2" events="162" subjects_affected="83" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="147" subjects_affected="119" subjects_at_risk="727"/>
                <counts group_id="E2" events="165" subjects_affected="117" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="38" subjects_affected="35" subjects_at_risk="727"/>
                <counts group_id="E2" events="37" subjects_affected="34" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="727"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>infections and infestations</sub_title>
                <counts group_id="E1" events="470" subjects_affected="281" subjects_at_risk="727"/>
                <counts group_id="E2" events="466" subjects_affected="249" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>injury, poisoning, and procedural complications</sub_title>
                <counts group_id="E1" events="238" subjects_affected="134" subjects_at_risk="727"/>
                <counts group_id="E2" events="218" subjects_affected="124" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="104" subjects_affected="81" subjects_at_risk="727"/>
                <counts group_id="E2" events="94" subjects_affected="70" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="78" subjects_affected="70" subjects_at_risk="727"/>
                <counts group_id="E2" events="87" subjects_affected="63" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>gamma glutamyltransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="54" subjects_affected="47" subjects_at_risk="727"/>
                <counts group_id="E2" events="71" subjects_affected="57" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>weight increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="727"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>investigations</sub_title>
                <counts group_id="E1" events="564" subjects_affected="215" subjects_at_risk="727"/>
                <counts group_id="E2" events="619" subjects_affected="214" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="208" subjects_affected="135" subjects_at_risk="727"/>
                <counts group_id="E2" events="136" subjects_affected="98" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="56" subjects_affected="50" subjects_at_risk="727"/>
                <counts group_id="E2" events="43" subjects_affected="37" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nervous system disorders</sub_title>
                <counts group_id="E1" events="246" subjects_affected="154" subjects_at_risk="727"/>
                <counts group_id="E2" events="151" subjects_affected="106" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="132" subjects_affected="102" subjects_at_risk="727"/>
                <counts group_id="E2" events="72" subjects_affected="54" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychiatric disorders</sub_title>
                <counts group_id="E1" events="162" subjects_affected="114" subjects_at_risk="727"/>
                <counts group_id="E2" events="129" subjects_affected="89" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory, thoracic, and mediastinal disorders</sub_title>
                <counts group_id="E1" events="105" subjects_affected="82" subjects_at_risk="727"/>
                <counts group_id="E2" events="80" subjects_affected="64" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="92" subjects_affected="75" subjects_at_risk="727"/>
                <counts group_id="E2" events="98" subjects_affected="75" subjects_at_risk="520"/>
              </event>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="727"/>
                <counts group_id="E2" events="44" subjects_affected="38" subjects_at_risk="520"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Walter Ling, M.D.</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>(310) 933-8111</phone>
      <email>lwalter@ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

